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Abstract
The Fluid Expansion as Supportive Therapy (FEAST
study) was an extremely well conducted study that
gave unexpected results. The investigators had reported
that febrile children with impaired perfusion treated in
low-income countries without access to intensive care
are more likely to die if they receive bolus resuscitation
with albumin or saline compared with no bolus
resuscitation at all. In a secondary analysis of the trial,
published in BMC Medicine, the authors found that
increased mortality was evident in patients who
presented with clinical features of severe shock in
isolation or in conjunction with features of respiratory or
neurological failure. The cause of excess deaths was
primarily refractory shock and not fluid overload. These
features are consistent with a potential cardiotoxic or
ischemia-reperfusion injury following resuscitation with
boluses of intravenous fluid. Although these effects may
have been amplified by the absence of invasive
monitoring, mechanical ventilation or vasopressors, the
results provide compelling insights into the effects of
intravenous fluid resuscitation and potential adverse
effects that extend beyond the initial resuscitation
period. These data add to the increasing body of
literature about the safety and efficacy of intravenous
resuscitation fluids, which may be applicable to
management of other populations of critically ill
patients.
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Background
The results of the Fluid Expansion as Supportive Therapy
(FEAST) trial [1] challenge many established principles
about using intravenous fluids for resuscitation. Con-
ducted in a pediatric population with compensated shock
under conditions of extreme deprivation, the study found
that bolus fluid resuscitation with albumin or saline was
associated with a statistically significant increase in mortal-
ity at four and 48 hours compared with no boluses of fluid.
These compelling results question well-established
recommendations for fluid boluses as a first-line interven-
tion in hemodynamic resuscitation, not only in pediatric
patients but also in all critically ill patients.
Debates and commentaries have questioned the general-
izability of these results in high-income countries where
invasive monitoring, mechanical ventilation and vasopres-
sors are standards of care [2]. Concerns have also been
expressed about the high proportion of patients with
severe malaria and anemia in the FEAST study and
whether the increased mortality was overly influenced by
this cohort of patients [3].
Interpreting these results in disparate populations
therefore requires further insights into the potential
mechanisms of increased death associated with bolus
resuscitation. The results presented in BMC Medicine by
Maitland et al. in this secondary analysis of the data in
the FEAST trial have been keenly awaited and are of high
importance [4].
Gaining insight into the FEAST trial results: objectives of
this study
The FEAST investigators considered that the increased
mortality could be primarily due to refractory shock and/or
the effects of fluid overload, particularly the development
of pulmonary or cerebral edema. They considered that sus-
ceptibility to increased mortality would depend on the
principal nature of the presenting syndrome (PS), charac-
terized by features of severe shock or acidosis, hypoxic
respiratory failure, or neurological causes such as seizures
* Correspondence: jmyburgh@georgeinstitute.org.au
1St George Clinical School, University of New South Wales, The George
Institute for Global Health, L13, 321 Kent Street, Sydney 2000, Australia
Full list of author information is available at the end of the article
Myburgh and Finfer BMC Medicine 2013, 11:67
http://www.biomedcentral.com/1741-7015/11/67
© 2013 Myburgh and Finfer; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
or coma. They defined terminal clinical events (TCE) at
the time of death to characterize the principal cause of
death according to cardiovascular, pulmonary or neurolo-
gical criteria. This characterization of the PS and TCE
using pragmatic, robust clinical criteria is unique and cen-
tral to the face validity of this sub-study. The investigators
also minimized bias by blinded adjudication of PS and
TCE - essential for an unblinded study - and adhered to
the principles of internal validity presented in the main
paper with minimal loss to follow up, intention-to-treat
analyses and no imputation for missing data.
Analyses were presented comparing bolus with no bolus
as mortality was similar for both albumin and saline
boluses, so elucidating differences in cause of death
between the two fluids was not possible from these results.
Results: cardiovascular collapse rather than fluid overload
contributes most to excess deaths with rapid fluid
resuscitation
Data are presented from a large cohort of patients (n =
2,396) who could be classified into a single or combination
of PSs. Of these, the most common PS was severe shock
or acidosis, either as a sole presentation or in combination
with other PSs. It was these patients, particularly those
with all three PSs, who had the highest mortality, suggest-
ing that shock at presentation had a significant impact on
mortality in both groups.
Of particular interest was the observation that there
appeared to be a short-term clinical benefit, namely reso-
lution of shock within one hour, in patients who received
boluses. However, this effect did not translate into
improved survival compared with those who did not
receive boluses; nor was there a difference in mortality
between patients who did and did not respond to fluid
boluses.
When patients were categorized according to the TCE,
the greatest difference in mortality was observed in
patients who received boluses and who died from cardio-
vascular causes, specifically terminal arrhythmia or hypo-
tension. This difference was greater in patients who died
in the first hour. Contrary to expectations, there was no
significant difference between patients who died primarily
from respiratory or neurological causes, suggesting that
fluid overload was not a predominant pathological
mechanism.
The increased risk of death with boluses and the TCEs
were similar in patients with or without malaria and with
or without anemia. Concern that the results were
restricted primarily to patients in low-income countries
with malaria or severe anemia is not supported by these
analyses. Consideration of cardiotoxic events of bolus fluid
resuscitation in other critically ill patients, particularly
those with severe sepsis, is therefore warranted.
Interpretation: how do these results inform clinicians
about potential pathological mechanisms associated with
fluid bolus resuscitation?
Clearly, fluid resuscitation is only one component of a
complex resuscitation strategy that is targeted at correcting
deficits in circulating blood and plasma volume, intrinsic
cardiac function and compensatory neurohormonal func-
tion. Under physiological conditions, the capacitant venous
system has the potential to generate increases in venous
return in response to hypovolaemia through sympatheti-
cally mediated responses - the ‘stressed’ volume [5,6].
The patients presented in this sub-study of the FEAST
study had impaired perfusion rather than decompensated
shock, which makes them a population of critically ill
patients with maximal compensatory mechanisms.
Although there was evidence of improved short-term
hemodynamic effects with boluses in these patients, bolus
administration may have resulted in a rapid reduction in
sympathetically mediated compensatory mechanisms,
leading to cardiovascular dysfunction and death.
An additional mechanism of increased cardiovascular
causes of death may relate to treatment-induced hyper-
chloremic metabolic acidosis. When infused rapidly and
in large volumes, albumin in saline carrier solutions may
have the same effect on chloride and acid-base status as
saline [7,8]. This effect is not seen when other crystalloid
solutions with more physiological strong ion differences
are infused [9].
The role of acidosis-induced cardiotoxicity remains
uncertain, but this effect, in conjunction with a potential
ischemia-reperfusion injury, may have been amplified in
this patient population where close monitoring of acid-
base status or support with mechanical ventilation or vaso-
pressors was not possible.
However, this does not exclude the possibility that rapid
high volume fluid resuscitation may be harmful under
conditions with more resources. Trials of fluid resuscita-
tion with colloids (albumin [10] and hydroxyethyl starch
[11,12]) in high-income countries have also demonstrated
transient improvements in indices of hemodynamic resus-
citation, but these have not been associated with improve-
ments in mortality or other patient-centered outcomes.
Furthermore, it appears that, as adjudicated by the
TCEs, fluid overload was not a predominant cause of
excess deaths in the patients in the FEAST study. This is
of interest, particularly the low incidence of neurological
causes of death. Although administration of albumin is
associated with increased mortality in patients with trau-
matic brain injury [13,14], this was not evident in this
patient population, even though a substantial proportion
of patients had severe cerebral malaria.
Although it appears that bolus resuscitation with albu-
min and saline in critically ill children in resource-poor
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conditions cannot be recommended, further high-quality
studies examining the effects of balanced salt solutions for
fluid resuscitation are required in this patient population.
Indeed, the question of the optimal resuscitation fluid,
both the type and dose, remains uncertain in all critically
ill patient population across all income regions.
Conclusions
This sub-study of the FEAST study has provided unique
insights into a critically important area of clinical medi-
cine. Fluid resuscitation is under increasing scrutiny fol-
lowing the publication of a number of randomized
controlled trials questioning the safety and efficacy of
widely used resuscitation fluids. The importance of these
findings make it imperative that clinicians carefully con-
sider the type, dosing and rate of administration of resusci-
tation fluids and monitor their effects beyond the initial
resuscitation period. Administration of resuscitation fluid
requires as much thought and care as the administration
of any other potentially lethal drug.
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